KOMET-007: ziftomenib in combination with venetoclax and azacitidine in R/R AML
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-12-08
Просмотров: 37
Описание:
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses the results of the KOMET-007 study (NCT05735184), which investigated ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory (R/R) NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML). Dr Wang highlights high response rates, with many patients achieving measurable residual disease negativity. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
